Synonym
Febuprol ; H-33; H 33; H33; NSC 30151; K-10033; K 10033; K10033.
IUPAC/Chemical Name
1-Butoxy-3-phenoxy-2-propanol
InChi Key
WBLXZPHICYCDGN-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H20O3/c1-2-3-9-15-10-12(14)11-16-13-7-5-4-6-8-13/h4-8,12,14H,2-3,9-11H2,1H3
SMILES Code
OC(COC1=CC=CC=C1)COCCCC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
224.30
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Jüngst D, Brenner G, Pratschke E, Paumgartner G. Lipid composition and cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones under choleretic treatment with Febuprol. Z Gastroenterol. 1988 May;26(5):275-8. PubMed PMID: 3407249.
2: Swobodnik W, Wechsler JG, Klüppelberg U, Janowitz P, Hutt V, Ditschuneit H. [Lithogenicity and bile acid pattern in choleretic administration (3-n-butoxy-1-phenoxy-propanol: febuprol) in patients with functional right upper quadrant pain]. Z Gastroenterol. 1987 Nov;25(11):715-20. German. PubMed PMID: 3324520.
3: Ritter U, Kyrein HJ. [Clinical trial of febuprol, a new substance with choleretic activity. Study of efficacy and tolerability]. Arzneimittelforschung. 1983;33(6):891-7. German. PubMed PMID: 6684447.
4: Scholing WE, Weinert W. [Clinical studies on the choleretic agent Febuprol (author's transl)]. MMW Munch Med Wochenschr. 1978 Feb 3;120(5):143-6. German. PubMed PMID: 342924.
5: Eisenburger R. [On the spasmolytic action of 3-butoxy-1-phenoxy-propanol-(2) (febuprol) on the biliary tract (author's transl)]. Arzneimittelforschung. 1977 Jul;27(7):1429-33. German. PubMed PMID: 578468.
6: Wolf C, Ritter U, Zschocke R, Weinert W. [Investigation of the choleretic action of febuprol on healthy test subjects (author's transl)]. MMW Munch Med Wochenschr. 1976 Oct 1;118(40):1285-8. German. PubMed PMID: 824554.
7: Rehm K, hempel K, Maurer-Schultze B, Schlemmer W. [On pharacokinetics and metabolism of the choleretic agent febuprol (author's transl)]. Arzneimittelforschung. 1976;26(5):813-20. German. PubMed PMID: 989353.
